Is Arbutus Biopharma Corp (ABUS) undervalued?
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
This page asks whether Arbutus Biopharma Corp (ABUS) looks cheap on cached numbers — not a DCF toy and not a buy alert.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. Cheap versus history or peers still needs a filing reason; a low multiple can be a value trap.
A new ABUS 10-Q can flip this screen overnight. The SEC page is the source.
Not investment advice. Compare ABUS to the stock page model before you treat a low multiple as a gift.
Not investment advice.